IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) reminds investors in CorMedix, Inc. (“CorMedix” or the “Company”) (NYSE: CRMD), who purchased or otherwise acquired shares between March 12, 2011 and July 29, 2015, inclusive (the “Class Period”), of the September 4, 2015, deadline to serve as lead plaintiff in the class action.
If you purchased shares of CorMedix during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at email@example.com.
There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.
According to the complaint, the Company allegedly made false and/or misleading statements and failed to disclose that: (1) the Company’s reports concerning its partnership discussions and imminent Phase 3 trials for its sole product, Neutrolin, were misleading; (2) studies touted by CorMedix overstated Neutrolin’s effectiveness; (3) CorMedix exaggerated the cost effectiveness of Neutrolin compared to established medical protocols; and (4) CorMedix stock traded at an artificially high level due to paid stock promoters who were not disclosed in regulatory filings.
When the truth was revealed to the public, the stock fell over 16% to close at $4.05 on June 29, 2015.
If you purchased shares of CorMedix during the Class Period you have until September 4, 2015, to ask the Court to appoint you as lead plaintiff. If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.